Wall Street analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report ($0.87) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.90) to ($0.82). Heron Therapeutics reported earnings per share of ($1.24) in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.8%. The company is expected to report its next quarterly earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($3.50) per share for the current fiscal year, with EPS estimates ranging from ($3.65) to ($3.36). For the next financial year, analysts anticipate that the firm will post earnings of ($2.21) per share, with EPS estimates ranging from ($3.52) to ($1.38). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million.

A number of brokerages have issued reports on HRTX. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Cowen and Company set a $40.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Aegis reissued a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $26.00 price objective on shares of Heron Therapeutics in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $31.00.

Shares of Heron Therapeutics (NASDAQ HRTX) opened at 16.40 on Friday. The stock has a 50 day moving average of $15.77 and a 200-day moving average of $14.76. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $20.85.

WARNING: “-$0.87 EPS Expected for Heron Therapeutics, Inc. (HRTX) This Quarter” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/28/0-87-eps-expected-for-heron-therapeutics-inc-hrtx-this-quarter.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC raised its position in Heron Therapeutics by 3.4% in the fourth quarter. Teachers Advisors LLC now owns 57,858 shares of the biotechnology company’s stock worth $758,000 after buying an additional 1,924 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock worth $330,000 after buying an additional 2,233 shares in the last quarter. Mesirow Financial Investment Management Equity Management acquired a new position in shares of Heron Therapeutics during the first quarter worth $435,000. Russell Investments Group Ltd. acquired a new position in shares of Heron Therapeutics during the first quarter worth $532,000. Finally, Rubric Capital Management LP raised its position in shares of Heron Therapeutics by 190.9% in the first quarter. Rubric Capital Management LP now owns 1,600,000 shares of the biotechnology company’s stock worth $24,000,000 after buying an additional 1,050,000 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.